# Study of High-dose Chemotherapy (HDC) Combined With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients

> **NCT01232062** · — · COMPLETED · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 46 (actual)

## Conditions studied

- Breast Neoplasms
- Neoplasm Metastasis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01232062
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2011-05
- **Final completion:** 2013-10
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2015-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01232062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01232062, "Study of High-dose Chemotherapy (HDC) Combined With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01232062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*